Another study showed that combined inhibition of MEK and CDK4/6 was effective in KRAS-mutant CRC PDXs and justified a phase II clinical trial in patients with refractory KRAS-mutant CRC [25,121]. The gene discussed is MAP2K7; the disease is colorectal carcinoma.